Retatrutide, a novel dual activator of the GLP-1 binding site and glucose-dependent released polypeptide (GIP) target, is demonstrating promising outcomes in initial clinical studies. Ongoing https://icelisting.com/story22629540/retatrutide-emerging-research-and-projected-medical-uses